China Pharma Univ. PARP1 compound 25d

China Pharma Univ. PARP1 compound 25d: sourced facts only. name: "Herein, we report the design and proof of concept of a highly potent dual Polθ/PARP inhibitor 25d, which exhibited low nanomolar inhibitory activities against both Polθ and PARP1." [PMID:38375763]; target: "Herein, we report the design and proof of concept of a highly potent dual Polθ/PARP inhibitor 25d, which exhibited low nanomolar inhibitory activities against both Polθ and PARP1." [PMID:38375763]; developer: "State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, College of Pharmacy, China Pharmaceutical University, Nanjing 211198, P. R. China." [PMID:38375763]; stage: "Compared to combination treatment, 25d demonstrated superior antitumor efficacy in both MDA-MB-436 cells and xenografts by inducing more DNA damage and apoptosis." [PMID:38375763]